ASH Participates in Roundtable Discussion With Senator Booker
On February 28, Sens. Tim Scott (R-SC) and Cory Booker (D-NJ) introduced the Sickle Cell Disease Surveillance, Prevention, and Treatment Act of 2018. To mark its introduction, Sen. Booker hosted a roundtable discussion in collaboration with the American Society of Hematology (ASH).
ASH Secretary Robert Brodsky, MD, joined two patients with sickle cell disease (SCD), a parent of a patient with SCD, and Biree Andemariam, MD, chief medical officer of the Sickle Cell Disease Association of America, to discuss upcoming research opportunities, share stories, and explain why the legislation is needed.
Visit Sen. Booker’s Facebook page (facebook.com/corybooker) to access a recorded version of the event.
Get Ready for the ASH Summit on Emerging Immunotherapies
The first-of-its-kind ASH Summit on Emerging Immunotherapies for Hematologic Diseases will take place July 12 to 13 in Washington, DC. Through breakout and didactic sessions, attendees will examine pre-clinical and clinical factors influencing the effective development, regulation, and implementation of immunotherapies for both malignant and non-malignant hematologic diseases. The interactive program aims to foster strategic collaborations among researchers, clinicians, regulators, industry scientists, and patient advocates. For more information and to register, visit hematology.org/meetings.
Available Now: The Hematologist App
Readers of The Hematologist can now enjoy great content on the go, and even offline! Download The Hematologist app and save your favorite articles to your smartphone or tablet.
Take notes, listen to podcasts, and more, with one convenient app – available at hematology.org/thehematologist/app.
Submit Your Nomination to Become an ASH Choosing Wisely Champion
In partnership with the American Board of Internal Medicine Foundation, ASH recognizes efforts of practitioners who are working to eliminate costly and potentially harmful overuse of common tests and procedures. The application cycle for the 2018 ASH Choosing Wisely Champions is now open. This year’s three Champions will present their strategies at the 60th ASH Annual Meeting and Exposition in San Diego. Clinicians, researchers, or trainees at all levels in both academic and community settings are encouraged to apply by June 1.
Visit hematology.org/ChoosingWisely for more information.
Blood Review Series on “Strategies to Improve GVL Effects”
The latest Blood review series explores developments in treatments to enhance graft-versus-leukemia effects in allogeneic hematopoietic cell transplantation, including cellular therapies, antibody-based treatments, and drug-based approaches using tyrosine kinase inhibitors and checkpoint blockade. The review series articles include:
Posttransplant chimeric antigen receptor therapy
Melody Smith, MD, Johannes Zakrzewski, MD, Scott James, MD, and Michel Sadelain, MD, PhD
Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation
Sarah Cooley, MD, Peter Parham, PhD, and Jeffrey S. Miller, MD
The potential role of γδ T cells after allogeneic HCT for leukemia
Rupert Handgretinger, MD, and Karin Schilbach, PhD
Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation
Robert J. Soiffer, MD, Matthew S. Davids, MD, and Yi-Bin Chen, MD
To read the entire series and watch a video highlight featuring Blood Associate Editor Robert Zeiser, MD, visit hematology.org/GVLreview.